.Pharmacolibrary.Drugs.ATC.C.C01BG11

Information

Vernakalant is an antiarrhythmic agent primarily used for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. It acts as a multichannel blocker and is approved for intravenous use in Europe, Canada, and several other regions.

Pharmacokinetics

Pharmacokinetic parameters in adult patients with atrial fibrillation following intravenous administration.

References

1. Mao, ZL, et al., & Keirns, J (2012). Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter. Journal of clinical pharmacology 52(7) 1042–1053. DOI:10.1177/0091270011408425 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21659624

2. Mao, Z, et al., & Keirns, JJ (2011). Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter. Journal of pharmacokinetics and pharmacodynamics 38(5) 541–562. DOI:10.1007/s10928-011-9207-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21786177

3. Akel, T, & Lafferty, J (2018). Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 23(3) e12508–None. DOI:10.1111/anec.12508 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29105209

Revisions

• 06/2025 initial generated model